Eganelisib: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{image- | |||
{{Infobox drug | |||
| name = Eganelisib | |||
| image = <!-- Image of the drug --> | |||
| alt = <!-- Alt text for the image --> | |||
| caption = <!-- Caption for the image --> | |||
| pronounce = <!-- Pronunciation --> | |||
| tradename = <!-- Trade names --> | |||
| synonyms = IPI-549 | |||
| legal_status = <!-- Legal status --> | |||
| routes_of_administration = <!-- Routes of administration --> | |||
| bioavailability = <!-- Bioavailability --> | |||
| protein_bound = <!-- Protein binding --> | |||
| metabolism = <!-- Metabolism --> | |||
| elimination_half-life = <!-- Elimination half-life --> | |||
| excretion = <!-- Excretion --> | |||
| CAS_number = <!-- CAS number --> | |||
| ATC_prefix = <!-- ATC code --> | |||
| ATC_suffix = <!-- ATC code --> | |||
| PubChem = <!-- PubChem ID --> | |||
| DrugBank = <!-- DrugBank ID --> | |||
| ChemSpiderID = <!-- ChemSpider ID --> | |||
| UNII = <!-- UNII --> | |||
| KEGG = <!-- KEGG ID --> | |||
| ChEBI = <!-- ChEBI ID --> | |||
| ChEMBL = <!-- ChEMBL ID --> | |||
| synonyms = IPI-549 | |||
}} | |||
'''Eganelisib''' (also known as '''IPI-549''') is an investigational drug that is being studied for its potential use in [[cancer]] treatment. It is a selective inhibitor of the [[PI3K-gamma]] enzyme, which plays a role in the [[immune system]] and [[tumor microenvironment]]. | |||
== Mechanism of Action == | |||
Eganelisib works by inhibiting the [[PI3K-gamma]] enzyme, which is involved in the regulation of [[immune cell]] activity within the [[tumor microenvironment]]. By targeting this enzyme, Eganelisib aims to modulate the immune response to enhance the body's ability to fight [[cancer]]. | |||
== Clinical Trials == | |||
Eganelisib is currently undergoing [[clinical trials]] to evaluate its safety and efficacy in combination with other [[cancer therapies]]. These trials are exploring its use in various types of [[cancer]], including [[breast cancer]], [[lung cancer]], and [[melanoma]]. | |||
== Research and Development == | |||
Eganelisib is being developed by [[Infinity Pharmaceuticals]], a company focused on the development of novel [[cancer therapies]]. The drug is part of a broader effort to develop targeted therapies that can improve outcomes for patients with [[cancer]]. | |||
== See Also == | |||
* [[PI3K inhibitors]] | |||
* [[Cancer immunotherapy]] | |||
* [[Tumor microenvironment]] | |||
== References == | |||
<references /> | |||
== External Links == | |||
* [Infinity Pharmaceuticals Website](https://www.infi.com) | |||
[[Category:Experimental cancer drugs]] | |||
[[Category:PI3K inhibitors]] | |||
[[Category:Immunotherapy]] | |||
Latest revision as of 21:40, 27 December 2024
| Eganelisib | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Eganelisib (also known as IPI-549) is an investigational drug that is being studied for its potential use in cancer treatment. It is a selective inhibitor of the PI3K-gamma enzyme, which plays a role in the immune system and tumor microenvironment.
Mechanism of Action[edit]
Eganelisib works by inhibiting the PI3K-gamma enzyme, which is involved in the regulation of immune cell activity within the tumor microenvironment. By targeting this enzyme, Eganelisib aims to modulate the immune response to enhance the body's ability to fight cancer.
Clinical Trials[edit]
Eganelisib is currently undergoing clinical trials to evaluate its safety and efficacy in combination with other cancer therapies. These trials are exploring its use in various types of cancer, including breast cancer, lung cancer, and melanoma.
Research and Development[edit]
Eganelisib is being developed by Infinity Pharmaceuticals, a company focused on the development of novel cancer therapies. The drug is part of a broader effort to develop targeted therapies that can improve outcomes for patients with cancer.
See Also[edit]
References[edit]
<references />
External Links[edit]
- [Infinity Pharmaceuticals Website](https://www.infi.com)
